BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates

87.71
0.4651
0.53 %
Daily range
Weekly range
  • Viktoras Karapetjanc
  • 13.10.2026
BNTX slides nearly 5% as seller pressure builds after disappointing trial results
BioNTech SE ADR (BNTX) dropped 4.79% after reporting that its Phase 2/3 trial for the mRNA cancer immunotherapy BNT113 failed to meet the first dual primary endpoint. The down move is supported by ...
  • Mykhailo Ihnatenko
  • 09.10.2026
BNTX climbs around 4.5% after investor focus shifts to late-stage cancer drugs
BioNTech SE ADR (BNTX) jumped 4.52% after expanding its oncology pipeline with more late-stage cancer drugs, a move that is broadening investor focus beyond vaccines. The rebound looks limited, ...
  • Sholanke Dele
  • 28.08.2026
Why is BioNTech stock down 7.8% today?
BioNTech SE ADR (BNTX) fell 7.85% after the company terminated a Phase 2 clinical trial for its individualized mRNA cancer immunotherapy in colorectal cancer, triggering a rapid reversal of ...
  • Ashutosh Sureka
  • 10.07.2026
SK Hynix readies U.S. market debut as NATO strains and Gulf shipping risks unsettle investors
Global markets are balancing fresh geopolitical stress with major corporate moves across technology and finance. Tensions around the Middle East and the NATO Summit are keeping energy supply risks ...
  • Dmytro Kharkov
  • 01.07.2026
BioNTech stock trades down as founders leave the company, raising transition concerns
BioNTech (BNTX) stock is trading at $93.05, down 1.28% on the day, and is currently positioned above its key short- and medium-term moving averages but remains below the ...